Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pyrrolidone derivatives.

S Shorvon1

  • 1Department of Clinical Neurology, Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, University College London, WC1, London, UK. s.shorvon@ion.ucl.ac.uk

Lancet (London, England)
|December 14, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 5th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures.

Epilepsy & behavior : E&B·2015
Same author

Genetic mutations associated with status epilepticus.

Epilepsy & behavior : E&B·2015
Same author

Preliminary results of the global audit of treatment of refractory status epilepticus.

Epilepsy & behavior : E&B·2015
Same author

EFNS guideline on the management of status epilepticus in adults.

European journal of neurology·2010
Same author

Risk factors for sudden unexpected death in epilepsy.

Epilepsia·2009
Same author

Limited chronic focal encephalitis: another variant of Rasmussen syndrome?

Neurology·2008
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
See all related articles

Pyrrolidones, including piracetam, are a class of drugs researched for cognitive enhancement and neuroprotection. Recent approvals for levetiracetam and piracetam signal a resurgence in their therapeutic applications.

Area of Science:

  • Pharmacology and Neuroscience
  • Drug Discovery and Development

Background:

  • The pyrrolidone (2-oxopyrrolidine) chemical family has been studied for over 30 years.
  • Initial research focused on nootropic effects (learning and memory enhancement).
  • Subsequent research explored neuroprotection and antiepileptic properties.

Purpose of the Study:

  • To review the historical and current research on the pyrrolidone class of drugs.
  • To highlight the reawakened interest in pyrrolidones due to recent clinical developments.
  • To discuss the potential for expanded clinical indications and new drug entries.

Main Methods:

  • Literature review of experimental and clinical studies on pyrrolidone compounds.
  • Analysis of historical research focusing on nootropic, neuroprotective, and antiepileptic effects.

Related Experiment Videos

  • Examination of recent developments including drug licensing and ongoing research.

    • Main Results:

    • Piracetam, the first nootropic, was developed in the late 1960s.
    • Pyrrolidones are distinguished by their lack of common adverse psychopharmacological actions.
    • Levetiracetam's approval as an antiepileptic and piracetam's use in stroke and cognitive impairment have renewed interest.
    • Several other pyrrolidone drugs are in advanced development.

    Conclusions:

    • The pyrrolidone class shows diverse therapeutic potential, including cognitive enhancement, neuroprotection, and epilepsy treatment.
    • Mechanisms of action may vary within the class and are still under investigation.
    • The field is experiencing a revival, suggesting broader clinical use and new drug introductions in the near future.